Page 1

NeuroScientific BIOPHARMACEUTICALS ASX : NSB ASX ANNOUNCEMENT 29 OCTOBER 2021 SEPTEMBER 2021 QUARTERLY ACTIVITY REPORT HIGHLIGHTS Reporting of significant EmtinBTM outcomes in pulmonary fibrosis studies and Multiple sclerosis biomarker studies Progress of preclinical safety studies of EmtinBTM with completion of Safety Pharmacology studies and initiation of 13 - week ocular toxicity study Two key drug development experts appointed to NeuroScientific's scientific advisory team Advance and Overseas Finding for the Company's ophthalmology R & D program Strong cash position with A $ 12.90M held as at 30 September 2021 NeuroScientific Biopharmaceuticals Ltd ( ASX : NSB ) ( " NeuroScientific ” or “ the company " ) today submitted its Appendix 4C and quarterly activity report for the period ended 30 September 2021 . Quarterly Activity Report During the September quarter , NeuroScientific continued to progress its preclinical R & D programs involving EmtinB ™ , including the reporting of positive outcomes in pulmonary fibrosis studies , the reporting of significant biomarker data in Multiple sclerosis studies , and the initiation of a 13 - week ocular toxicity study in non - human primates ( NHPs ) . The Company also expanded its scientific advisory team to include key international experts and received an Advance and Overseas Finding for its ocular R & D program to receive R & D rebates on up to $ 25 million of R & D expenditure . The Company reported outcomes from its preclinical pulmonary fibrosis studies , with significant reductions of > 50 % in inflammatory markers associated with COVID - 19 infections . Significant reductions were demonstrated in inflammatory markers Serum Amyloid A ( SAA ) , Interferon - gamma - inducible protein - 10 ( CXCL10 / IP - 10 ) , and Eotaxin 3 ( Eot3 ) . Safety studies undertaken by the Institute for Respiratory Health also confirmed that EmtinBTM was safe and well tolerated in lung tissue . Also during the September quarter , NeuroScientific reported biomarker data that indicated significant reductions in the dysfunctional immune responses associated with Multiple sclerosis ( MS ) . In preclinical assays of T Cell inflammation , EmtinB ™ reduced important MS - related biomarkers CXCL10 / IP - 10 , Matrix Metalloproteinase - 9 ( MMP - 9 ) , Immunoglobulin G ( IgG ) , and decreased Th1 - mediated cell proliferation . NeuroScientific continued to progress the preclinical safety studies for both neurology and ophthalmology R & D programs involving EmtinB ™ , with the completion of GLP NeuroScientific Biopharmaceuticals Ltd ABN : 13 102 832 995 Suite 5 , 85 Forrest Street , Cottesloe WA 6011 www.neuroscientific.com ir@neuroscientific.com info@neuroscientific.com